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Stem cells and other innovative intra-articular





Osteoarthritis (OA), the most common type of arthritis in the world, is associated with suffering due to pain,
productivity loss, decreased mobility and quality of life. Systemic therapies available for OA are mostly symptom
modifying and have potential gastrointestinal, renal, hepatic, and cardiac side effects. BMC Musculoskeletal Disorders
recently published a study showing evidence of reparative effects demonstrated by homing of intra-articularly
injected autologous bone marrow stem cells in damaged cartilage in an animal model of OA, along with clinical
and radiographic benefit. This finding adds to the growing literature showing the potential benefit of intra-articular
(IA) bone marrow stem cells. Other emerging potential IA therapies include IL-1 receptor antagonists, conditioned
autologous serum, botulinum toxin, and bone morphogenetic protein-7. For each of these therapies, trial data in
humans have been published, but more studies are needed to establish that they are safe and effective. Several
additional promising new OA treatments are on the horizon, but challenges remain to finding safe and effective
local and systemic therapies for OA.
Please see related article: http://www.biomedcentral.com/1471-2474/12/259
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Background
Osteoarthritis (OA) is the most common type of arthri-
tis and the leading cause of disability in the United
States [1]. OA alone is responsible for $3.4 to $13.2 bil-
l i o ni nj o b - r e l a t e dc o s t se v e r yy e a ri nt h eU S .[ 2 , 3 ]a n d
is associated with significant healthcare utilization, defi-
cits in quality of life, and productivity loss [4-7]. Several
systemic treatments, mostly symptom-modifying rather
than disease-modifying agents, are available for OA [8].
Recently published OA treatment guidelines highlight
t h es t r e n g t ho fe v i d e n c ef o rv a r i o u st h e r a p i e s[ 9 - 1 2 ] .
However, there is a real need for effective, safe, disease-
modifying OA therapies that can not only effectively
treat those with established OA, but also possibly delay
or prevent progression in those with early OA [13].
None of the potential therapies discussed in this
editorial have been approved by regulatory agencies
such as the US Food and Drug Administration (FDA),
and therefore these therapies are experimental.
Stem cells for OA: a potential new treatment on
the horizon?
Stem cells can differentiate into different cell lineages due
to their self-renewing and clonogenic capabilities [14].
Embryonic stem cells have the capability to differentiate
into any terminally differentiated cell in the body [15].
Adult stem cells were originally believed to only differenti-
ate into tissue-specific cells. However adult stem cells may
be programmed under specific signals to differentiate into
other organ-specific cells with a phenotype distinct from
that of the precursor. Certain barriers that exist to achiev-
ing this effectively in vivo must be overcome, namely, easy
accessibility to sufficient concentration of stem cells at the
site of tissue repair and generation of appropriate signals
from the tissue repair site directing the cells to the site
[15]. Stem cells can be administered via systemic intravas-
cular route or a direct local implantation, such as that
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any medium, provided the original work is properly cited.done to repair infracted myocardium [16,17] and in spinal
cord injuries [18]. In a recent study by Mokbel et al. in
BMC Musculoskeletal Disorders, labeled autologous adult
stem cells suspended in hyaluronic acid were injected
intra-articularly into carpal joints in an experimental
arthritis induced by intra-articular (IA) Amphotericin-B in
donkeys [19]. Significant improvement was noted in clini-
cal and radiographic OA and significantly lesser histo-
pathological changes of OA were seen in carpal joints that
received IA autologous mesenchymal stem cells compared
to control contralateral joints that received IA hyaluronic
acid [19]. Importantly, injected stem cells were incorpo-
rated into the articular cartilage of the injected joint, as
evident by their integration in the surface of the cartilage
and also the interior of the cartilage. Interestingly, while
some of these cells showed a chondrocyte-like phenotype
indicating their differentiation, other injected cells retained
spindle-like structure, characteristic of the mesenchymal
origin. Previous studies have suggested that bone marrow
and synovial mesenchymal stem cells have more chondro-
genic potential compared to adipose or muscle mesenchy-
mal stem cells [20]. While other studies have provided
evidence that stem cells may offer potential therapeutic
benefit in OA [21,22], challenges remain in the translation
of this knowledge into available therapies for patients with
OA. The challenges include homing of adequate number
of cells in the tissues undergoing repair, long-term safety
of such approaches especially those using viral vectors, the
durability of the benefit, and feasibility of providing these
treatments in busy practitioners’ offices. Despite the chal-
lenges in bringing this potential therapy to clinic, stem cell
therapy offers a revolutionary approach to the treatment
of OA.
New pharmacotherapies for intra-articular use in
osteoarthritis
While stem cell therapy may constitute a potential ther-
apy for OA patients in the future, there is need for addi-
tional new effective and safe treatment options. Currently
available systemic treatments for OA symptoms are com-
monly associated with gastrointestinal, hepatic, renal,
and/or cardiac adverse events, especially in the elderly
[8]. This makes IA and local therapies attractive options,
especially for patients with limited OA in the knee or hip
joints. The counter-argument is that OA is a systemic
disease in many patients with involvement of several
joints, and therefore there is also a great need for new
systemic therapies. Additionally, IA administration may
provide a higher concentration of the medication in the
joint macro and micro environment, including the carti-
lage and synovium, and avoid several systemic adverse
events [23]. The disadvantage of rare infection following
IA injection (0.002%) [24] is far outweighed by its advan-
tages. We discuss a few interesting potential new IA
therapies with evidence of early efficacy in human OA. A
more complete list is provided in Table 1.
Interluekin-1 beta (IL-1b), thought to play an impor-
tant role in OA pathology, was targeted with IL-1 recep-
tor antagonist administered IA (at 2 doses, 50 mg and
150 mg) as a single injection in 170 patients [25] and an
antibody against IL-1 administered subcutaneously every
4 weeks for three months in 149 patients [26] in one pla-
cebo-controlled randomized controlled trial (RCT) each.
There were no significant differences in the primary out-
come, the Western Ontario McMaster Arthritis Index
(WOMAC) scores, at 4-6 weeks follow-up between treat-
ment and placebo groups, in either study. Biochemical
and histopathogical changes, including decrease in syno-
vial inflammation and hypertrophy, reduction in highly
sensitive C-reactive protein and increase in proteoglycan
content, were noted in the patients who received the
active treatment. A high placebo response and short half-
life of the molecule in the joint may be partially responsi-
ble for lack of an effect. It remains to be seen whether
modifying the available preparations of IL-1b and/or tar-
geting other cytokine targets in addition to IL-1b,c a n
provide an effective treatment option.
There has been significant recent interest in the use of
autologous conditioned serum, which is derived by incu-
bating patient’s serum with glass beads to induce the
release of several anti-inflammatory cytokines such as IL-1
receptor antagonist, IL-4, IL-10, and IL-13, centrifuged
and injected intra-articularly into the joints. However, the
early results from two RCTs in humans are contradictory.
One RCT of six IA injections showed no significant differ-
ence in WOMAC scores (primary outcome) compared to
IA saline [27], while the other RCT reported significantly
better outcome in IA autologous conditioned serum
group, compared to IA hyaluronic acid or IA saline [28].
Another interesting approach is the use of IA botuli-
num toxin, which is hypothesized to have antinocicep-
tive and possibly anti-inflammatory action. In three
RCTs of a single IA injection of botulinum toxin in to
43-60 painful joints each (with painful OA or painful
arthroplasty with OA as the underlying condition), clini-
cally and statistically significant improvements in pri-
mary outcome of pain as well as extremity function (on
WOMAC and shoulder indices) were noted in IA botu-
linum toxin group (with or without lidocaine) compared
to control treatment (saline or saline plus lidocaine)
[29-31]. In another RCT, IA botulinum toxin had effi-
cacy similar to IA corticosteroid [32]. Botulinum toxin
is known to inhibit substance P and calcitonin-gene
related protein [33-36], the main mediators of neuro-
genic inflammation, a phenomenon of vasodilatation,
protein extravasation, and stimulation of inflammatory
cells induced by antidromic stimulation of primary affer-
ent fiber [37].
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genetic protein-7 (BMP-7). In a phase I tolerability and
safety study, IA recombinant human BMP-7 showed a
higher response rate in treatment compared to the pla-
cebo group [38]. Other innovative therapies including
human platelet-rich plasma [39,40], fibroblast growth
factor-18 (FGF-18) [41,42], platelet-derived growth fac-
tor (PDGF) [43], and insulin-like growth factor (IGF)
[43] are being tested in early (animal and early human)
studies for their potential to repair cartilage (Table 1).
Conclusions: we are not there yet, but we are on
our way
T h ei n t e r e s t i n gs t u d yb yM o k b e let al. [18] provides
additional evidence from animal models for the poten-
tial of autologous mesenchymal bone marrow stem cells
as a potential future treatment for OA. Early evidence
from human RCTs is also available for additional IA
t h e r a p i e ss u c ha sI L - 1 b antagonists, autologous condi-
tioned serum and botulinum toxin. Whether these
approaches will translate into effective and safe therapies
for humans remains to be seen. This next step will need
more convincing evidence of therapeutic efficacy and
safety in humans in large RCTs and correlation with
improvements in disease pathophysiology, with the use
of serum and joint biomarkers and/or imaging biomar-
kers (radiographs, magnetic resonance imaging, and so
on). The future of OA therapeutics seems bright, with a
lot of potential therapies targeting different mechanisms
of action, different pathways and different approaches
for this disabling disease.
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Table 1 Emerging intra-articular therapies for osteoarthritis
Therapy/Drug development stage Proposed mechanism of action
Evidence from Human Studies
Interleukin-1 (IL-1) inhibitor [25,26,44]
2 Phase II/III trials
Inhibition of IL-1, a pro-inflammatory cytokine that promotes cartilage degradation
Human autologous conditioned serum [27,28]
2 Phase II/III trials
Production of anti-inflammatory cytokines such as IL-1 receptor antagonist, IL-4, IL-10, and IL-13
Botulinum toxin [29-32]
3 Phase II/III trials
Inhibition of release of release of Substance P, calcitonin gene-related protein and glutamate from
primary afferent neuron terminals
Recombinant human bone morphogenetic
protein-7 (BMP-7) [38,45]
1 Phase I trial
Stimulation of proteoglycan, collagen and hyaluronic acid synthesis; induction of receptors,
prevention of catabolism of cartilage components by interleukin (IL)-1
Human platelet rich plasma (PRP) [39,40]
Case series (n = 14)
Stimulation of chondrogenesis, increase in hyaluronic acid production, stabilization of angiogenesis
Evidence from Animal Models
Fibroblast growth factor-18 (FGF-18) [41,42,46] Stimulation or stabilization of bio-synthesis of cartilage matrix components
Platelet-derived growth factor (PDGF) [43] Increase in cell proliferation and proteoglycan production; stimulation of meniscal cell proliferation
and migration
Insulin-like growth factor (IGF) [42,43,47] Improvement in cartilage homeostasis by balancing proteoglycan synthesis and breakdown;
reduction in synovial inflammation
Caspase inhibitors [48,49] Inhibition of chondrocyte death apoptosis
Human Kallistatin [50] Suppression of inflammatory responses and reduce cell apoptosis
Interleukin-6 (IL-6) inhibitor [51] Inhibition of hypoxia-inducible factor 2 alpha-induced cartilage destruction by regulating matrix
metalloproteinase 3 (MMP3) and MMP13
Recombinant human PRG4 (rhPRG4) [52] Replacement of lubricin, that has lubricant and anti-adhesive properties and is chondroprotective
Recombinant human OPG (rHuOPG) [53] Suppression of chondrocyte apoptosis
Leptin [54] Stimulation of synthesis of IGF-1 and TGF beta1 to stimulate chondrocytes to repair extracellular
matrix
Mu-opioid receptor [55] Reduction of substance P and neurotransmitter release from sensory nerve endings peripherally and
centrally
Dehydroepiandrosterone [56] Modulate the imbalance between matrix metalloproteinases (MMPs) and tissue inhibitor of
metalloproteinases 1 (TIMP-1)
Berberine, a traditional Chinese medication
[57]
Reduction of MMP-3 and MMP-13 levels
Evidence from in vitro studies
Fibroblast growth factor-2 (FGF-2) [58] Stimulation of chondrocyte progenitor cells
N-acetylcysteine [59] Increase in chondrocyte viability by reducing oxidative damage
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